BioCentury
ARTICLE | Clinical News

Zalviso regulatory update

July 14, 2014 7:00 AM UTC

Partner Gruenenthal Group (Aachen, Germany) submitted an MAA to EMA for Zalviso to manage moderate to severe acute pain in adults in a medically supervised environment. The submission triggered a $5 ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article